CompletedNCT00191399
Olanzapine with fluoxetine for depression in bipolarity
About this title
Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response
Read the official source — NCT00191399Medication studyAges 18+United States
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Seattle and 9 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMay 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 150
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00191399
- Official title
Show the full official title
Bipolar Depression Assessment Study on Tx Response
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Seattle, United States · Bayamón, Puerto Rico · Caguas, Puerto Rico
7 more locations
- Canovanas, Puerto Rico
- Hato Rey, Puerto Rico
- Manati, Puerto Rico
- Mayagüez, Puerto Rico
- Rio Piedras, Puerto Rico
- San Juan, Puerto Rico
- Santurce, Puerto Rico
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine and Fluoxetine.
Who was this study for?
Listed age limits: from 18 years.
